Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Debuts Eliquis Rival In Canada

Apo-Apixaban Version Is First Generic Alternative Available

Executive Summary

Apotex has introduced Canada’s first generic version of Eliquis in the form of its Apo-Apixaban product. The launch comes after the firm was also among a wave of Aubagio teriflunomide generics to hit the Canadian market.

You may also be interested in...



OTC Private Label, Rx Generics Firm Apotex To Be Acquired By Private Investment Group

SK Capital announced agreement to acquire Apotex, saying it will invest to “support Apotex’s next phase of growth and continued innovation for patient affordability."

Canada’s Apotex Is Snapped Up By SK Capital

Apotex is to be acquired by SK Capital, the private investment firm has announced. The Canadian generics giant’s new owner has promised to invest in the firm to “support Apotex’s next phase of growth and continued innovation for patient affordability.”

BMS Plans Appeal After Sandoz And Teva Eliminate UK Eliquis Patent

While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel